Identifying Prognostic Markers for Heart Failure in Patients with Kidney Disease
Plasma Proteomic Signature and the Prognosis of Acute Heart Failure With or Without Chronic Kidney Disease
This study is trying to find out if certain blood markers can help predict how well heart failure patients with kidney disease will do in the hospital compared to those without kidney issues.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 155 (estimated) |
| Ages | 20 Years to 90 Years |
| Sex | All |
| Sponsor | Cheng-Hsin General Hospital Academic / other |
| Locations | 1 site (Taipei, Baitou District) |
| Trial ID | NCT06006819 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the prognostic markers associated with acute heart failure (AHF) in patients who also have chronic kidney disease (CKD). It focuses on comparing the plasma proteomic signatures of hospitalized AHF patients with and without CKD to better predict patient outcomes. The study utilizes N-terminal pro-brain natriuretic peptide (NT-pro-BNP) as a known prognostic marker, while also exploring its limitations in CKD patients. By analyzing these biomarkers, the study seeks to enhance understanding of the underlying pathophysiology and improve prognostic accuracy for this patient population.
Who should consider this trial
Good fit: Ideal candidates for this study are hospitalized patients experiencing acute heart failure who also have chronic kidney disease.
Not a fit: Patients with initial serum NT-proBNP levels below 300 ng/ml, those who are pregnant, amputated, or in end-stage renal disease requiring regular dialysis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostic tools for managing acute heart failure in patients with chronic kidney disease.
How similar studies have performed: While the study explores a novel approach by integrating plasma proteomics with existing biomarkers, similar studies have shown promise in improving prognostic accuracy in related conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * hospitalized for acute heart failure Exclusion Criteria: * initial serum NT-proBNP level \<300ng/ml, pregnancy, amputated, and end-stage renal disease under regular dialysis
Where this trial is running
Taipei, Baitou District
- Cheng Hsin General Hospital — Taipei, Baitou District, Taiwan (Recruiting)
Study contacts
- Principal investigator: Shang Feng Yang, MD — Cheng-Hsin General Hospital
- Study coordinator: Shang Feng Yang, MD
- Email: samyang1223@gmail.com
- Phone: +886-22826-4400
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.